Annotated Clinical Bibliography: The Evidence Base for Psychiatric Deprescribing
A technical compendium of peer-reviewed papers, clinical textbooks, and regulatory directives establishing the pharmacological reality of neuroadaptive withdrawal and the necessity of hyperbolic titration.
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz MA, Taylor D. The Lancet Psychiatry. 2019 Jun; 6(6): 538–546. DOI: 10.1016/S2215-0366(19)30032-X
Methodological Summary: Evaluated PET radioligand studies examining Serotonin Transporter (SERT) occupancy across citalopram, fluoxetine, sertraline, paroxetine, and venlafaxine. Proved that receptor occupancy follows a hyperbolic Michaelis-Menten profile. Concluded that linear reductions produce steep collapses in receptor occupancy at low doses, mathematically validating the 10% exponential decay reduction model down to fractions of a milligram.
The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs
Taylor D, Horowitz MA. Oxford: Wiley-Blackwell; 2024. ISBN: 978-1-119-82298-1.
Clinical Significance: The first authoritative clinical reference textbook written for physicians on safe psychiatric deprescribing. Details compound-by-compound tapering schedules, commercial oral solution conversion tables, compounding formulations, and clinical management of protracted withdrawal.
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D. Schizophrenia Bulletin. 2021 Jul; 47(4): 1116–1129. DOI: 10.1093/schbul/sbab017
Methodological Summary: Analyzed PET imaging of striatal dopamine D2 receptor occupancy for haloperidol, olanzapine, risperidone, clozapine, and quetiapine. Demonstrated that D2 blockade mirrors the hyperbolic curve of SSRIs. Concluded that rapid antipsychotic reduction triggers dopamine supersensitivity psychosis, validating hyperbolic titration down to micro-doses to maintain stable D2 disengagement.
Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual)
Ashton CH. Department of Psychiatry, University of Newcastle upon Tyne; 2002.
Clinical Significance: Derived from twelve years of direct clinical management of more than 300 chronically dependent patients in a dedicated withdrawal clinic. Established the pharmacology of Diazepam substitution, equivalence ratios across all major benzodiazepines and Z-drugs, and detailed managing protracted withdrawal symptoms.
Medicines associated with dependence or withdrawal symptoms: safe prescribing and managing withdrawal (NG215)
National Institute for Health and Care Excellence (NICE). London: NICE; Published April 2022.
Regulatory Directive: Formally superseded earlier guidelines claiming withdrawal resolves in two weeks. Mandates that deprescribing must be patient-directed, gradual, and use proportionate step reductions. Recognizes that withdrawal symptoms can be severe, last for months, and are frequently misdiagnosed as illness relapse.
A systematic review into the incidence, severity and duration of antidepressant withdrawal effects
Davies J, Read J. Addictive Behaviors. 2019 Oct; 97: 111–121. DOI: 10.1016/j.addbeh.2018.08.027
Meta-Analytic Findings: Synthesized data across 14 clinical studies. Found that 56.4% of patients discontinuing antidepressants experienced withdrawal, and 45.7% of those categorized symptoms as severe. Rebutted historical claims that antidepressant withdrawal is rare or self-limiting.